About Us
The Company

EveryWord International was founded in 2014.
Headquartered in New York, the company is the sole owner of EveryWord™.
EveryWord™  a multilingual mobile Smartphone suite of mHealthcare applications for anyone who needs to monitor speech and language acquisition and usage.
EveryWord International is guided by an Advisory Board of leading experts in their respective fields. Most Advisory Board members have been collaborating for approximately 7 years. Collectively the Advisory Board members represent major academic and clinical centers. Experts are recruited in countries where EveryWord International is active.
Helping people regardless of age, gender, language, and location.

© 2014, EveryWord International. All rights reserved.  EveryWord®, EveryWord Kids®, and EveryWord Adults® are registered trademarks of; EveryWord International.

Entrepreneurs

EveryWord™’s two co-founders bring the necessary ingredients for the success of this first ever project designed to improve and preserve the life of young and old members of the globe’s human population. Together they possess thorough knowledge of the technology available and needed to achieve the clinical goals while complying with law and regulations world-wide.

Dov Topaz

Has over than 25 years of video based systems experience in developing new products; establish new companies and implementing new ideas. Dov was one of the founders (patent inventor) of CountWise, people counting solutions, and Agent Vi video intelligence systems,Dov served as the Video Product Manager for Magal Ltd. a global leader in Perimeter protection systems. Dov was in charge of video engineering at Peek when it was the second world largest company in traffic control.

Ephraim Katz PhD

Has 18 years experience in drug development in the US with under graduate degree in Sociology, Psychology and PhD in Neuroscience (NYU). Ephraim has extensive experience with all stages of drug development (pre-licensing evaluations, pre-clinical, all phases of early and late clinical trials including post-marketing) and compliance with domestic and international regulatory agencies including multiple face-to-face meetings, ‘clinical hold’ resolution, and pediatric written requests (PWRs). Ephraim has served in diverse roles including global lead of active strategy planning for entering the Alzheimer’s disease (AD) market, supervised early stage development in Transient Ischemic Attack (TIA) preventing medication, and most recently oversaw clinically, scientifically, and operationally a global clinical development program in autism spectrum disorder (ASD). Prior to accepting a position in the pharmaceutical industry Ephraim held academic positions.


Mr. Topaz and Dr. Katz are assembling the best group of experts needed for this ambitious project. Contributing to their ability to bridge the diverse areas of expertise is their life-long friendship.

Advisors:
  • Michael Amman, PhD

    Professor Emeritus of Psychology, Ohio State University, Columbus, Ohio Co-developer of the Aberrant Behavior Checklist (ABC).

  • Antonio Hardan, MD

    Director, Division of Child and Adolescent Psychiatry 
    Director, Autism and Developmental Disabilities Clinic
    Professor, Department of Psychiatry and Behavioral Sciences
    Stanford University, Palo Alto, CA

  • Robert L. Hendren, DO

    rofessor and Vice Chair
    Director, Child and Adolescent Psychiatry
    Director, Autism and Neurodevelopment Program
    Co-Director, Dyslexia Center
    University of California, San Francisco
    UCSF Benioff Children's Hospital

  • Raun D. Melmed, MD, FAAP

    Director, Melmed Center, Scottsdale, AZ
    Co-founder, Medical Director, Southwest Autism Research and Resource Center, Phoenix, AZ

  • Orna Mick, MA

    Chief Pediatric Comunication Clinician (Audiology), Rambam Medical Center, Haifa, Israel
    Chief Communication Clinician (communication and language deficiencies), Milman Center for children with developmental deficiencies, Autism Spectrum, Haifa, Israel